Group 5D: Triple Negative Breast Cancer; Immunotherapy; Tumor Immune Microenvironment; Treatment Outcomes

Poster #P1-09-20: Enhancer of zeste homologue 2 (EZH2) inhibition in Triple Negative Breast Cancer (TNBC) attenuates tumor growth in vitro and in vivo altering the tumor immune microenvironment.

Poster #P3-10-03: Real-world first-line immunotherapy use and overall survival rates for triple-negative breast cancer: analyses from a 2018-2020 US population-based cohort